Business Wire - Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect from April 2008
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the “Pharmaceutical Pricing and Distribution in Japan: The keys to success in the world’s second largest market” report to their offering.
No serious multinational can afford to ignore Japan, but it remains a tough and highly competitive market to crack, with the environment for developing and marketing medicines dominated by price. Virtually no new prescription brand can be introduced without a yakka (reimbursement price) set by the government. Innovative new drugs receive price premiums while others are capped at the price of older entrants. Discounting to the trade is inescapable, but is punished by downward price revisions on a scale and frequency unseen elsewhere. Big selling brands and now others in the same class are subject to special price cuts. Distribution is inherently linked to the pricing process and is particularly opaque to outsiders.
Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
5 Regular Mistakes In Public Speaking
13 Job Interview Mistakes To Avoid
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
Whether the challenge is entering the Japanese market for the first time, moving up the all-important ranking there by market share, or negotiating with a local in-licensing partner, this report is designed to help.
- New drug pricing and price revision processes explained
- Written by an acknowledged expert on the Japanese market with 20 years’ experience
- Fully researched through field interviews conducted in Tokyo and Osaka with industry leaders, government officials and others during March 2008
- Incorporates all pricing rule changes that came into effect from April 2008
- Pro-generic measures critically appraised
- Key role of wholesalers and how they are paid clarified
- Prospects for future reform to the P&R processes discussed
Key Topics Covered:
1. Organisation & Funding of Healthcare System
2. Regulatory Environment
3. Pharmaceutical Business Environment
4. Launch Price Setting
5. Price Revision Process
6. Other Cost Containment Methods
7. Other Market Segments
8. Distribution
9. Future Prospects
List of tables
List of figures
Companies Mentioned:
Astellas
AstraZeneca
Banyu
Bayer-Schering
Boehringer Ingelheim
BMS
Chugai
Daiichi-Sankyo
Dainippon Sumitomo
Eisai
GSK
Hisamitsu
Hospira
Janssen
Kyowa
Hakko Kirin
Meiji Seika
Mitsubishi-Tanabe
Mylan
Nichi-Iko
Novartis
Ono
Otsuka
Pfizer
Roche
Sanofi-Aventis
Sandoz
Sato
Sawai
Servier
Shionogi
SolvaySuntory
SSP
Taiho
Taisho
Taiyo Yakuhin
Takeda
Teva
Towa
Yakult Honsha
Yoshitomi
Zeria
Products covered
Abilify
Aldurazyme
Amlodin
Aricept
Avastin
Blopress
Campto
Clarith
Claritin
Coversyl
Crestor
Depromel
Diovan
Doral
Enbrel
Epogin
Evista
Exjade
Fabrazyme
Farom
Funguard
Gaster
Glivec
Harnal
Iressa
J-Zoloft
Lantus
Leuplin
Lipitor
Luvox
Maxalt
Mevalotin
Micardis
Mohrus Tape
Myozyme
Naglazyme
Nexavar
Nicotinell TTS
Norvasc
Nu-Lotan
Olmetec
Omepral
Pariet
Paxil
Pegasys
Preminent
Prograf
Radicut
Relenza
Remicade
Renivace
Revatio
Risperdal
Somavert
Sutent
Takepron
Taxol
Topotecin
Tracleer
Valtrex
Vesicare
Viagra
Zetia
Zoloft
Zovirax.
For more information visit http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri
COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
